Format

Send to

Choose Destination
See comment in PubMed Commons below
J Rheumatol. 2012 Nov;39(11):2153-6. doi: 10.3899/jrheum.120482. Epub 2012 Sep 15.

Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID).

Author information

1
Department of Rheumatology and Clinical Immunology, University of Würzburg, Würzburg, Germany. Roll_P@klinik.uni-wuerzburg.de

Abstract

OBJECTIVE:

Rituximab (RTX) therapy is a treatment option in patients with refractory antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We investigated the tolerability and clinical efficacy of RTX in a cohort of patients with refractory AAV.

METHODS:

Clinical and safety data of patients with AAV treated with RTX were retrospectively assessed from the data of a German national registry.

RESULTS:

In total, 58 patients were included in this analysis (50/58 with granulomatosis with polyangiitis; 8/58 with microscopic polyangiitis who received at least 1 cycle, 17 patients who received 2 cycles, and 3 patients who received 3 cycles of RTX). Response was classified as complete and partial in 22 (40%) and in 29 cases (52.7%), respectively. Four patients (7.3%) were classified as nonresponders.

CONCLUSION:

RTX was well tolerated with good clinical efficacy in patients with refractory AAV.

PMID:
22984269
DOI:
10.3899/jrheum.120482
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center